{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:42:13Z","timestamp":1790167333383,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a plasma cell malignancy characterized by bone pain and end-organ failure. A major challenge in treating MM is therapeutic resistance. CD38-targeted immunotherapies, such as daratumumab, have significantly improved outcomes; however, variable responses, resistance, and relapse remain vital challenges. We hypothesized that loss of CD38 drives a more aggressive phenotype and resistance to therapy. To test this, we developed a CD38 knockout (KO) clone of a human MM cell line and evaluated it in immunodeficient mice. Mice with CD38 KO tumors exhibited an increased tumor burden and reduced survival compared with those with CD38 wild-type (WT) tumors. Multimodal imaging and histologic analyses revealed increased osteolytic lesions caused by CD38 KO tumors, while [18F]-fluorodeoxyglucose positron emission tomography demonstrated elevated metabolic activity and tracer uptake. Mice with CD38 KO tumors also developed bilateral renal metastases, whereas none were observed in WT tumors. Blood analysis showed elevated markers of disease progression and renal dysfunction, and cytokine profiling identified increased proinflammatory cytokines within the bone microenvironment. RNA sequencing identified marked transcriptional changes, with enrichment of pathways involving cell adhesion, cytokine signaling, and migration. Daratumumab-resistant MM.1S cells mirrored CD38 KO cells with reduced cell cycle progression and dexamethasone sensitivity, underscoring the microenvironment\u2019s role in driving aggressiveness, and implicating CD38 loss as a possible mediator of cross-resistance. Overall, these findings demonstrate that CD38 loss drives an aggressive MM phenotype characterized by bone degradation, renal metastasis, and reduced survival, highlighting the need to develop strategies to target CD38-deficient clones and identifying RNA signatures as potential regulators of this phenotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017296","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:58:38Z","timestamp":1759867118000},"page":"343-355","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4824-5076","authenticated-orcid":false,"given":"Michael R.","family":"Dyer","sequence":"first","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1054-3768","authenticated-orcid":false,"given":"Alex","family":"Zheleznyak","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin N.","family":"Teubner","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Prior","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Manion","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7153-8419","authenticated-orcid":false,"given":"Zhenghan","family":"Jing","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit K.","family":"Sharma","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Du","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"},{"name":"2Institute of Materials Science & Engineering, Washington University in St Louis, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-1003","authenticated-orcid":false,"given":"Rui","family":"Tang","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Fiala","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0429-3133","authenticated-orcid":false,"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"},{"name":"4Oncologic Imaging Program, Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Veis","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-8052","authenticated-orcid":false,"given":"Julie","family":"O\u2019Neal","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"},{"name":"4Oncologic Imaging Program, Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-2487","authenticated-orcid":false,"given":"Mikhail Y.","family":"Berezin","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"},{"name":"2Institute of Materials Science & Engineering, Washington University in St Louis, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Shokeen","sequence":"additional","affiliation":[{"name":"1Department of Radiology, Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO"},{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO"},{"name":"4Oncologic Imaging Program, Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital, St Louis, MO"},{"name":"5Department of Biomedical Engineering, Washington University in St Louis, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"1","key":"2026012709465620700_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026012709465620700_bib2","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026012709465620700_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2026012709465620700_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-017-1990-2","article-title":"The multi-faceted potential of CD38 antibody targeting in multiple myeloma","volume":"66","author":"Shallis","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2026012709465620700_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026012709465620700_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms24010645","article-title":"Innovative anti-CD38 and anti-BCMA targeted therapies in multiple myeloma: mechanisms of action and resistance","volume":"24","author":"De Novellis","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026012709465620700_bib7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2026012709465620700_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","article-title":"Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"2026012709465620700_bib9","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2016.02.037","article-title":"Loss of CD38 expression in relapsed refractory multiple myeloma","volume":"16","author":"Ise","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2026012709465620700_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2026012709465620700_bib11","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2026012709465620700_bib12","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1182\/bloodadvances.2023011295","article-title":"Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma","volume":"7","author":"Portuguese","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026012709465620700_bib13","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate","year":"2021","journal-title":"Cancer Sci"},{"issue":"5","key":"2026012709465620700_bib14","first-page":"1743","article-title":"Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma","volume":"92","author":"Rao","year":"1998","journal-title":"Blood"},{"key":"2026012709465620700_bib15","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3389\/fimmu.2018.01676","article-title":"CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance","volume":"9","author":"Seckinger","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2026012709465620700_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.31083\/j.fbl2701021","article-title":"Decrease of CD38 expression is linked to increase of solitary plasmacytoma pathological grade: a single institution experience from China","volume":"27","author":"Li","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"2026012709465620700_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/ejh.12902","article-title":"CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy","volume":"99","author":"Minarik","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026012709465620700_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13550-021-00840-4","article-title":"In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET","volume":"11","author":"Ghai","year":"2021","journal-title":"EJNMMI Res"},{"issue":"4","key":"2026012709465620700_bib19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s11307-024-01901-5","article-title":"Development of new CD38 targeted peptides for cancer imaging","volume":"26","author":"Zheleznyak","year":"2024","journal-title":"Mol Imaging Biol"},{"issue":"20","key":"2026012709465620700_bib20","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2023010032","article-title":"Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc","volume":"7","author":"O\u2019Neal","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026012709465620700_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J Nucl Med"},{"key":"2026012709465620700_bib22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","article-title":"Tissue processing and hematoxylin and eosin staining","volume":"1180","author":"Feldman","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2026012709465620700_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00418-014-1272-4","article-title":"Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts and osteocytes","volume":"143","author":"Solberg","year":"2015","journal-title":"Histochem Cell Biol"},{"key":"2026012709465620700_bib24","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.11.579390","article-title":"Identification drug targets for oxaliplatin-induced cardiotoxicity without affecting cancer treatment through inter variability cross-correlation analysis (IVCCA)","author":"Du","year":"12  2024","journal-title":"bioRxiv"},{"issue":"4","key":"2026012709465620700_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp Hematol"},{"issue":"3","key":"2026012709465620700_bib26","first-page":"335","article-title":"Characterization of a novel myeloma cell line, MM.1","volume":"113","author":"Goldman-Leikin","year":"1989","journal-title":"J Lab Clin Med"},{"issue":"3","key":"2026012709465620700_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11307-025-01984-8","article-title":"Correction: preclinical development of near-infrared-labeled CD38-targeted daratumumab for optical imaging of CD38 in multiple myeloma","volume":"27","author":"Cho","year":"2025","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"2026012709465620700_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00256-015-2268-4","article-title":"Vertebral lesion distribution in multiple myeloma--assessed by reduced-dose whole-body MDCT","volume":"45","author":"Bier","year":"2016","journal-title":"Skeletal Radiol"},{"issue":"8","key":"2026012709465620700_bib29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","article-title":"Imaging of bone metastasis: an update","volume":"7","author":"O'Sullivan","year":"2015","journal-title":"World J Radiol"},{"issue":"8","key":"2026012709465620700_bib30","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/annonc\/mdp603","article-title":"Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency","volume":"21","author":"Khan","year":"2010","journal-title":"Ann Oncol"},{"issue":"5-6","key":"2026012709465620700_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000090185","article-title":"Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations","volume":"28","author":"Haller","year":"2005","journal-title":"Kidney Blood Press Res"},{"issue":"12","key":"2026012709465620700_bib32","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"issue":"2","key":"2026012709465620700_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"2026012709465620700_bib34","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.43","article-title":"A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function","volume":"25","author":"Vallet","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"2026012709465620700_bib35","doi-asserted-by":"crossref","first-page":"e158874","DOI":"10.1172\/jci.insight.158874","article-title":"Increased joint loading induces subchondral bone loss of the temporomandibular joint via the RANTES-CCRs-Akt2 axis","volume":"7","author":"Feng","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"2026012709465620700_bib36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10875-014-0053-0","article-title":"Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets \u2013 a review of the current knowledge","volume":"34","author":"Varzaneh","year":"2014","journal-title":"J Clin Immunol"},{"issue":"5","key":"2026012709465620700_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41590-024-01808-x","article-title":"An IL-1\u03b2-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma","volume":"25","author":"de Jong","year":"2024","journal-title":"Nat Immunol"},{"issue":"20","key":"2026012709465620700_bib38","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood.2025028963","article-title":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma","volume":"146","author":"Rivera","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026012709465620700_bib39","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O'Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2026012709465620700_bib40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules--the lifelines of multiple myeloma cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2026012709465620700_bib41","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma","volume":"38","author":"Sun","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"2026012709465620700_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ejcb.2016.10.002","article-title":"Netrin-1: a regulator of cancer cell motility?","volume":"95","author":"Ylivinkka","year":"2016","journal-title":"Eur J Cell Biol"},{"issue":"41","key":"2026012709465620700_bib43","doi-asserted-by":"crossref","first-page":"14463","DOI":"10.1523\/JNEUROSCI.3018-11.2011","article-title":"A signaling mechanism coupling netrin-1\/deleted in colorectal cancer chemoattraction to SNARE-mediated exocytosis in axonal growth cones","volume":"31","author":"Cotrufo","year":"2011","journal-title":"J Neurosci"},{"key":"2026012709465620700_bib44","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/343\/2497936\/blooda_adv-2025-017296-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/343\/2497936\/blooda_adv-2025-017296-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:47:07Z","timestamp":1769525227000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/343\/547631\/Ablation-of-CD38-in-multiple-myeloma-cells-leads"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017296","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,14]]}}}